1. Home
  2. GCTS vs NXTC Comparison

GCTS vs NXTC Comparison

Compare GCTS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCT Semiconductor Holding Inc.

GCTS

GCT Semiconductor Holding Inc.

HOLD

Current Price

$1.29

Market Cap

60.5M

Sector

Finance

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$12.83

Market Cap

49.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTS
NXTC
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.5M
49.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GCTS
NXTC
Price
$1.29
$12.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$3.50
$23.00
AVG Volume (30 Days)
8.6M
24.5K
Earning Date
01-01-0001
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,239.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.23
52 Week High
$2.47
$15.74

Technical Indicators

Market Signals
Indicator
GCTS
NXTC
Relative Strength Index (RSI) 59.68 58.08
Support Level $1.26 $10.40
Resistance Level $1.37 $13.47
Average True Range (ATR) 0.09 1.04
MACD 0.01 0.24
Stochastic Oscillator 72.54 67.19

Price Performance

Historical Comparison
GCTS
NXTC

About GCTS GCT Semiconductor Holding Inc.

GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: